Carsten Thiel has been appointed CEO of Abeona Therapeutics (NASDAQ: [[ticker:ABEO]]). He succeeds Timothy Miller, who will remain president of the Dallas-based company and also take on new duties as chief scientific officer. Thiel comes to Abeona from New Haven, CT-based Alexion Pharmaceuticals (NASDAQ: [[ticker:ALXN]]), where he was executive vice president and chief commercial officer. Abeona develops cell and gene therapies for rare genetic diseases. The company’s lead programs include EB-101 to treat the skin disorder epidermolysis bullosa, and ABO-102, a gene therapy intended to treat Sanflilppo syndrome, an enzyme deficiency disorder.
